FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

This study is comparing two different chemotherapy strategies for people with colorectal cancer that has spread to the liver and cannot be surgically removed. One approach delivers chemo directly into the liver artery (hepatic arterial infusion, or HAI) plus IV chemo; the other uses a standard full-body chemo regimen. Both may include the targeted drug bevacizumab. **You may be eligible if...** - You have confirmed colorectal cancer with liver metastases that cannot be removed by surgery - Your cancer has RAS or BRAF mutations - You have not previously received chemotherapy for your liver metastases **You may NOT be eligible if...** - You have had previous treatment specifically for your liver metastases - You have cancer that has spread beyond the liver - You have serious liver or blood clotting problems Talk to your doctor to see if this trial is right for you.